It's Showtime for Medtronic
Medtronic (NYS: MDT) is expected to report Q3 earnings on Feb. 19. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medtronic's revenues will grow 2.9% and EPS will expand 8.3%.
The average estimate for revenue is $4.03 billion. On the bottom line, the average EPS estimate is $0.91.
Last quarter, Medtronic tallied revenue of $4.10 billion. GAAP reported sales were 1.8% higher than the prior-year quarter's $4.02 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.88. GAAP EPS of $0.63 for Q2 were 23% lower than the prior-year quarter's $0.82 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.1%, 100 basis points worse than the prior-year quarter. Operating margin was 28.3%, 20 basis points worse than the prior-year quarter. Net margin was 15.8%, 590 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $16.53 billion. The average EPS estimate is $3.67.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,706 members out of 1,797 rating the stock outperform, and 91 members rating it underperform. Among 531 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 519 give Medtronic a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medtronic is outperform, with an average price target of $45.20.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Medtronic. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Medtronic to My Watchlist.
The article It's Showtime for Medtronic originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.